Empire Dermatology

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)7 trials
• Psoriasis2 trials
• Vitiligo2 trials
• Alopecia areata1 trial
• Hidradenitis suppurativa1 trial

Phase

• Phase 35 trials
• Phase 22 trials
• Phase 41 trial

Status

• Completed4 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Incyte Corporation3 trials
• Amgen2 trials
• Pfizer2 trials
• Evommune, Inc.1 trial
• Target PharmaSolutions, Inc.1 trial

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

  NCT07783425· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  NCT06113445· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  NCT05995964· Phase 2· Pfizer· Source

• Active, not recruiting

  A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  NCT03661866· Target PharmaSolutions, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting

Closed trials

• Completed

  Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

  NCT07150845· Phase 2· Evommune, Inc.· Source

• Completed

  A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

  NCT06088199· Phase 3· Amgen· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Terminated

  The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

  NCT05696392· Phase 4· Incyte Corporation· Source

• Completed

  Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Phase 3· Incyte Corporation· Source